Posted by Michael Wonder on 03 Sep 2021
FDA acceptance for filing of new drug application for trientine tetrahydrochloride for the treatment of Wilson’s disease
2 September 2021 - New drug application supported by positive data from Phase 3 CHELATE clinical trial.
Orphalan today announces that the US FDA has accepted for review the Company’s new drug application for trientine tetrahydrochloride for the first-line treatment of Wilson’s disease.
